{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:07:28Z","timestamp":1793142448547,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Institute of Neurological Disorders and Stroke of the National Institutes of Health","award":["1R61NS113258, R33NS113258"],"award-info":[{"award-number":["1R61NS113258, R33NS113258"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14901-7","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:53:24Z","timestamp":1760525604000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Longitudinal multi-omics analyses of chemotherapy-induced peripheral neuropathy in response to taxanes"],"prefix":"10.1186","volume":"25","author":[{"given":"Anukriti","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alper","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bihua","family":"Bie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily E.","family":"Rhoades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Steenblik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"DeVecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Hershberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Lynn","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Bou","family":"Dargham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Thomas","family":"Budd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Foss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Rotroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"issue":"17","key":"14901_CR1","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1002\/cncr.32175","volume":"125","author":"KA Nyrop","year":"2019","unstructured":"Nyrop KA, Deal AM, Reeder-Hayes KE, Shachar SS, Reeve BB, Basch E, et al. Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: current clinical practice. Cancer. 2019;125(17):2945\u201354.","journal-title":"Cancer"},{"issue":"6","key":"14901_CR2","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ana.24951","volume":"81","author":"NP Staff","year":"2017","unstructured":"Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. 2017;81(6):772\u201381.","journal-title":"Ann Neurol"},{"issue":"Suppl 1","key":"14901_CR3","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/j.pain.0000000000001540","volume":"160 Suppl","author":"LA Colvin","year":"2019","unstructured":"Colvin LA. Chemotherapy-induced peripheral neuropathy: where are we now? Pain. 2019;160 Suppl(Suppl 1):S1-s10.","journal-title":"Pain"},{"key":"14901_CR4","doi-asserted-by":"crossref","unstructured":"Lee KT, Bulls HW, Hoogland AI, James BW, Colon-Echevarria CB, Jim HSL. Chemotherapy-Induced Peripheral Neuropathy (CIPN): a narrative review and proposed theoretical model. Cancers (Basel). 2024;16(14):2571","DOI":"10.3390\/cancers16142571"},{"issue":"3","key":"14901_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1053\/j.seminoncol.2021.09.004","volume":"48","author":"S Zhang","year":"2021","unstructured":"Zhang S. Chemotherapy-induced peripheral neuropathy and rehabilitation: a review. Semin Oncol. 2021;48(3):193\u2013207.","journal-title":"Semin Oncol"},{"issue":"4","key":"14901_CR6","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1007\/s13311-021-01142-2","volume":"18","author":"EH Bae","year":"2021","unstructured":"Bae EH, Greenwald MK, Schwartz AG. Chemotherapy-induced peripheral neuropathy: mechanisms and therapeutic avenues. Neurotherapeutics. 2021;18(4):2384\u201396.","journal-title":"Neurotherapeutics"},{"key":"14901_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/164_2022_609","volume":"277","author":"CS Chen","year":"2023","unstructured":"Chen CS, Hertz DL. Chemotherapy-induced peripheral neuropathy. Handb Exp Pharmacol. 2023;277:299\u2013337.","journal-title":"Handb Exp Pharmacol"},{"issue":"12","key":"14901_CR8","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","volume":"155","author":"M Seretny","year":"2014","unstructured":"Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461\u201370.","journal-title":"Pain"},{"key":"14901_CR9","doi-asserted-by":"publisher","first-page":"153303382211271","DOI":"10.1177\/15330338221127169","volume":"21","author":"A Sharma","year":"2022","unstructured":"Sharma A, Johnson KB, Bie B, Rhoades EE, Sen A, Kida Y, et al. A multimodal approach to discover biomarkers for Taxane-induced peripheral neuropathy (TIPN): a study protocol. Technol Cancer Res Treat. 2022;21:15330338221127168.","journal-title":"Technol Cancer Res Treat"},{"key":"14901_CR10","doi-asserted-by":"publisher","first-page":"1139883","DOI":"10.3389\/fpain.2023.1139883","volume":"4","author":"KB Johnson","year":"2023","unstructured":"Johnson KB, Sharma A, Henry NL, Wei M, Bie B, Hershberger CE, et al. Genetic variations that influence paclitaxel pharmacokinetics and intracellular effects that may contribute to chemotherapy-induced neuropathy: a narrative review. Front Pain Res. 2023;4:1139883.","journal-title":"Front Pain Res"},{"issue":"1","key":"14901_CR11","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s13311-020-00931-5","volume":"18","author":"Y Yang","year":"2021","unstructured":"Yang Y, Wen J, Zheng B, Wu S, Mao Q, Liang L, et al. CREB participates in paclitaxel-induced neuropathic pain genesis through transcriptional activation of Dnmt3a in primary sensory neurons. Neurotherapeutics. 2021;18(1):586\u2013600.","journal-title":"Neurotherapeutics"},{"key":"14901_CR12","doi-asserted-by":"crossref","unstructured":"Araldi D, Staurengo-Ferrari L, Bogen O, Bonet IJM, Green PG, Levine JD. Mu-Opioid Receptor (MOR) dependence of pain in chemotherapy-induced peripheral neuropathy. J Neurosci. 2024;44(42):e0243242024.","DOI":"10.1523\/JNEUROSCI.0243-24.2024"},{"key":"14901_CR13","doi-asserted-by":"publisher","first-page":"117515","DOI":"10.1016\/j.biopha.2024.117515","volume":"180","author":"L Kim","year":"2024","unstructured":"Kim L, Nan G, Kim HY, Cha M, Lee BH. Modulation of chemotherapy-induced peripheral neuropathy by JZL195 through glia and the endocannabinoid system. Biomed Pharmacother. 2024;180:117515.","journal-title":"Biomed Pharmacother"},{"key":"14901_CR14","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1186\/1471-2407-14-993","volume":"14","author":"SB Park","year":"2014","unstructured":"Park SB, Kwok JB, Loy CT, Friedlander ML, Lin CSY, Krishnan AV, et al. Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes. BMC Cancer. 2014;14:993.","journal-title":"BMC Cancer"},{"issue":"6","key":"14901_CR15","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/annonc\/mdt018","volume":"24","author":"DL Hertz","year":"2013","unstructured":"Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, et al. CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol. 2013;24(6):1472\u20138.","journal-title":"Ann Oncol"},{"issue":"18","key":"14901_CR16","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1158\/1078-0432.CCR-12-1590","volume":"18","author":"RM Baldwin","year":"2012","unstructured":"Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res. 2012;18(18):5099\u2013109.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"14901_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1136\/jmedgenet-2012-101466","volume":"50","author":"LJ Leandro-Garc\u00eda","year":"2013","unstructured":"Leandro-Garc\u00eda LJ, Inglada-P\u00e9rez L, Pita G, Hjerpe E, Leskel\u00e4 S, Jara C, et al. Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. J Med Genet. 2013;50(9):599\u2013605.","journal-title":"J Med Genet"},{"key":"14901_CR18","doi-asserted-by":"publisher","first-page":"864910","DOI":"10.3389\/fpain.2022.864910","volume":"3","author":"RL Rodwin","year":"2022","unstructured":"Rodwin RL, Siddiq NZ, Ehrlich BE, Lustberg MB. Biomarkers of chemotherapy-induced peripheral neuropathy: current status and future directions. Front Pain Res (Lausanne). 2022;3:864910.","journal-title":"Front Pain Res (Lausanne)"},{"issue":"1","key":"14901_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.cyto.2012.03.027","volume":"59","author":"XM Wang","year":"2012","unstructured":"Wang XM, Lehky TJ, Brell JM, Dorsey SG. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine. 2012;59(1):3\u20139.","journal-title":"Cytokine"},{"issue":"1","key":"14901_CR20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12974-021-02131-0","volume":"18","author":"R Chen","year":"2021","unstructured":"Chen R, Yin C, Fang J, Liu B. The NLRP3 inflammasome: an emerging therapeutic target for chronic pain. J Neuroinflammation. 2021;18(1):84.","journal-title":"J Neuroinflammation"},{"key":"14901_CR21","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3389\/fonc.2020.00416","volume":"10","author":"Z Duan","year":"2020","unstructured":"Duan Z, Zhang J, Li J, Pang X, Wang H. Inhibition of microRNA-155 reduces neuropathic pain during chemotherapeutic bortezomib via engagement of neuroinflammation. Front Oncol. 2020;10:416.","journal-title":"Front Oncol"},{"key":"14901_CR22","doi-asserted-by":"crossref","unstructured":"Noda-Narita S, Shimomura A, Tanabe Y, Kawauchi J, Matsuzaki J, Takizawa S, Aoki Y, Shimizu C, Tamura K, Ochiya T. Peripheral neuropathy from paclitaxel: risk prediction by serum microRNAs. BMJ Support Palliat Care. 2020;14(e2):e001900","DOI":"10.1136\/bmjspcare-2019-001900"},{"issue":"3","key":"14901_CR23","doi-asserted-by":"publisher","first-page":"e0248942","DOI":"10.1371\/journal.pone.0248942","volume":"16","author":"JW Huang","year":"2021","unstructured":"Huang JW, Kuo CH, Kuo HC, Shih JY, Tsai TW, Chang LC. Cell metabolomics analyses revealed a role of altered fatty acid oxidation in neurotoxicity pattern difference between nab-paclitaxel and solvent-based paclitaxel. PLoS ONE. 2021;16(3):e0248942.","journal-title":"PLoS ONE"},{"issue":"1","key":"14901_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12974-021-02098-y","volume":"18","author":"Y Li","year":"2021","unstructured":"Li Y, Yin C, Liu B, Nie H, Wang J, Zeng D, et al. Transcriptome profiling of long noncoding RNAs and mRNAs in spinal cord of a rat model of paclitaxel-induced peripheral neuropathy identifies potential mechanisms mediating neuroinflammation and pain. J Neuroinflammation. 2021;18(1):48.","journal-title":"J Neuroinflammation"},{"key":"14901_CR25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.neulet.2014.10.014","volume":"596","author":"VA Carozzi","year":"2015","unstructured":"Carozzi VA, Canta A, Chiorazzi A. Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms? Neurosci Lett. 2015;596:90\u2013107.","journal-title":"Neurosci Lett"},{"issue":"8","key":"14901_CR26","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","volume":"41","author":"TJ Postma","year":"2005","unstructured":"Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer. 2005;41(8):1135\u20139.","journal-title":"Eur J Cancer"},{"issue":"10","key":"14901_CR27","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1007\/s11136-013-0379-8","volume":"22","author":"EM Lavoie Smith","year":"2013","unstructured":"Lavoie Smith EM, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL. Assessing patient-reported peripheral neuropathy: the reliability and validity of the European organization for research and treatment of cancer QLQ-CIPN20 questionnaire. Qual Life Res. 2013;22(10):2787\u201399.","journal-title":"Qual Life Res"},{"issue":"16_suppl","key":"14901_CR28","doi-asserted-by":"publisher","first-page":"12003","DOI":"10.1200\/JCO.2023.41.16_suppl.12003","volume":"41","author":"MS Trivedi","year":"2023","unstructured":"Trivedi MS, Unger JM, Hershman DL, Darke A, Hertz DL, Brannagan T, et al. Chemotherapy induced peripheral neuropathy (CIPN) due to paclitaxel versus docetaxel in patients with early-stage breast cancer receiving taxane therapy: SWOG S1714. J Clin Oncol. 2023;41(16_suppl):12003\u201312003.","journal-title":"J Clin Oncol"},{"issue":"21","key":"14901_CR29","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1200\/JCO.2013.49.1514","volume":"31","author":"F Mols","year":"2013","unstructured":"Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol. 2013;31(21):2699\u2013707.","journal-title":"J Clin Oncol"},{"issue":"2","key":"14901_CR30","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1093\/annonc\/mds329","volume":"24","author":"G Cavaletti","year":"2013","unstructured":"Cavaletti G, Cornblath DR, Merkies ISJ, Postma TJ, Rossi E, Frigeni B, et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol. 2013;24(2):454\u201362.","journal-title":"Ann Oncol"},{"key":"14901_CR31","unstructured":"R Core Team: A language and environment for statistical computing (Version 4.2). R Foundation for Statistical Computing. In: R Foundation for Statistical Computing. 2022."},{"issue":"5","key":"14901_CR32","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/ana.24265","volume":"76","author":"AS Beutler","year":"2014","unstructured":"Beutler AS, Kulkarni AA, Kanwar R, Klein CJ, Therneau TM, Qin R, et al. Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy. Ann Neurol. 2014;76(5):727\u201337.","journal-title":"Ann Neurol"},{"issue":"1\u20132","key":"14901_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jns.2015.06.056","volume":"357","author":"GK Boora","year":"2015","unstructured":"Boora GK, Kulkarni AA, Kanwar R, Beyerlein P, Qin R, Banck MS, et al. Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance). J Neurol Sci. 2015;357(1\u20132):35\u201340.","journal-title":"J Neurol Sci"},{"issue":"15","key":"14901_CR34","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1093\/bioinformatics\/btac403","volume":"38","author":"AA Metwally","year":"2022","unstructured":"Metwally AA, Zhang T, Wu S, Kellogg R, Zhou W, Contrepois K, et al. Robust identification of temporal biomarkers in longitudinal omics studies. Bioinformatics. 2022;38(15):3802\u201311.","journal-title":"Bioinformatics"},{"issue":"4","key":"14901_CR35","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","volume":"30","author":"A Kr\u00e4mer","year":"2014","unstructured":"Kr\u00e4mer A, Green J, Pollard J Jr, Tugendreich S. Causal analysis approaches in Ingenuity pathway analysis. Bioinformatics. 2014;30(4):523\u201330.","journal-title":"Bioinformatics"},{"issue":"2","key":"14901_CR36","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/bioinformatics\/btab664","volume":"38","author":"A Bodein","year":"2022","unstructured":"Bodein A, Scott-Boyer MP, Perin O. KA LC, Droit A: timeomics: an R package for longitudinal multi-omics data integration. Bioinformatics. 2022;38(2):577\u20139.","journal-title":"Bioinformatics"},{"issue":"11","key":"14901_CR37","first-page":"3537","volume":"25","author":"J Le-Rademacher","year":"2017","unstructured":"Le-Rademacher J, Kanwar R, Seisler D, Pachman DR, Qin R, Abyzov A, et al. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel\/carboplatin-induced peripheral neuropathy in NCCTG\/Alliance clinical trials. Support Care Cancer. 2017;25(11):3537\u201344.","journal-title":"Support Care Cancer"},{"issue":"15","key":"14901_CR38","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1158\/1078-0432.CCR-18-0656","volume":"24","author":"DL Hertz","year":"2018","unstructured":"Hertz DL, Kidwell KM, Vangipuram K, Li F, Pai MP, Burness M, et al. Paclitaxel plasma concentration after the first infusion predicts treatment-limiting peripheral neuropathy. Clin Cancer Res. 2018;24(15):3602\u201310.","journal-title":"Clin Cancer Res"},{"key":"14901_CR39","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.neuropharm.2018.07.002","volume":"139","author":"Y Mulpuri","year":"2018","unstructured":"Mulpuri Y, Marty VN, Munier JJ, Mackie K, Schmidt BL, Seltzman HH, et al. Synthetic peripherally-restricted cannabinoid suppresses chemotherapy-induced peripheral neuropathy pain symptoms by CB1 receptor activation. Neuropharmacology. 2018;139:85\u201397.","journal-title":"Neuropharmacology"},{"key":"14901_CR40","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejon.2018.09.003","volume":"36","author":"CW Chan","year":"2018","unstructured":"Chan CW, Cheng H, Au SK, Leung KT, Li YC, Wong KH, et al. Living with chemotherapy-induced peripheral neuropathy: uncovering the symptom experience and self-management of neuropathic symptoms among cancer survivors. Eur J Oncol Nurs. 2018;36:135\u201341.","journal-title":"Eur J Oncol Nurs"},{"issue":"2","key":"14901_CR41","doi-asserted-by":"publisher","first-page":"125","DOI":"10.6004\/jnccn.2022.7074","volume":"21","author":"T Li","year":"2023","unstructured":"Li T, Timmins HC, Trinh T, Mizrahi D, Harrison M, Horvath LG, et al. Patient-reported outcome measures in chemotherapy-induced peripheral neurotoxicity: defining minimal and clinically important changes. J Natl Compr Canc Netw. 2023;21(2):125-132.e123.","journal-title":"J Natl Compr Canc Netw"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14901-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14901-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14901-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:53:26Z","timestamp":1760525606000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14901-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14901"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14901-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and ethical approval was granted by the Institutional Review Board (IRB) of Cleveland Clinic (IRB# 20\u2013908). Informed consent was obtained from all participants prior to their inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"D.M.R. has received research support from Novo Nordisk and Bayer Pharmaceuticals, has equity in Clarified Precision Medicine, and Genovation Health, LLC and owns intellectual property related to liver cancer and type 2 diabetes. K.B.J. has received research support from Medtronic, has equity in Applied Medical Visualizations, LLC, is on the advisory board of Senzime, is a board examiner for the American Board of Anesthesiology, the Section Editor of International Anesthesia Research Society\u2013Anesthesia and Analgesia, and on the Editorial Board of the International Anesthesia Research Society. J.F. has received consulting honoraria from MCG Health. N.L.H. is a consultant for AstraZeneca and receives royalties from Up-to-Date.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1591"}}